profit from every $100 of sales.
$0$100
OptimizeRx
$7.34-17.25% today
-52.5% in 1 year
1-year low $4.541-year high $15.46
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $26.94 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What OptimizeRx sold, what it kept, and what it did with the cash.
Sales went from $62.5 million in 2022 to $109 million in 2025, with $5.13 million of profit last year.
SalesProfit
OptimizeRx vs. similar companies
OptimizeRx grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| OptimizeRx | 26.9× · Fair price | ||
 GE HealthCare Technologies | 18.0× · Fair price | ||
 BrightSpring Health Services | 74.3× · Very expensive | ||
 Tempus AI | No profit yet | ||
 HealthEquity | 39.8× · Expensive |
AI analysis
An AI analyst reads OptimizeRx's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 62 | 72 | 92 | 109 | |
| 39 | 43 | 59 | 74 | |
| -12 | -18 | -6 | 12 | |
| -9 | -21 | -9 | 17 | |
| -11 | -18 | -20 | 5 | |
| -0.64 | -1.03 | -1.10 | 0.27 | |
| 62.4% | 60.0% | 64.5% | 67.3% | |
| -19.7% | -24.5% | -6.7% | 11.0% | |
| -18.3% | -24.6% | -21.8% | 4.7% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 135 | 183 | 171 | 177 |
| Cash | 18 | 14 | 13 | 23 |
| Total debt | 0 | 37 | 33 | 26 |
| Total liabilities | 9 | 57 | 54 | 49 |
| 126 | 127 | 117 | 128 | |
| 18 | 17 | 18 | 19 | |
| -7.2% | -11.5% | -7.0% | 6.3% | |
| -9.1% | -13.9% | -17.2% | 4.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 11 | -7 | 5 | 19 | |
| 0 | 1 | 0 | – | |
| 10 | -8 | 4 | 19 | |
| Dividends paid | – | – | – | – |
| 20 | 8 | 0 | – | |
| 16 | 14 | 11 | 7 |
Valuation
- 26.9×
- 7.8×
- –
- 0.9×
- 1.3×
- 7.4×
- 8.5×
- 13.5%
- 3.7%
- 0.0%
Profitability
- 67.3%
- 11.0%
- 4.7%
- 15.4%
- 6.5%
- -5.9%
- 5.5%
- 4.1%
- 9.3%
- 3.2%
Growth
- +20.6%
- –
- +290.6%
- –
- +1.9%
Financial health
- 0.2×
- 0.02
- 1.4%
- 5.1×
- 5.37
- 5.37
- 0.64
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 45%of 952
Top 46%of 884
Bottom 49%of 601
Top 26%of 886
Top 5%of 987
What analysts expect
- Average price target
- $17.00
- Range
- $17.00 – $17.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | 0.14 | 0.01 | +1,300.0% |
| Mar 5, 2026 | 0.51 | 0.23 | +121.7% |
| Nov 6, 2025 | 0.20 | 0.03 | +566.7% |
| Aug 7, 2025 | 0.24 | 0.03 | +700.0% |
| May 12, 2025 | 0.08 | -0.11 | +172.7% |
| Mar 12, 2025 | 0.30 | 0.25 | +20.0% |
| Nov 13, 2024 | 0.12 | 0.06 | +100.0% |
| Aug 8, 2024 | 0.02 | -0.07 | +128.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
56No pass
Benjamin Graham
62Pass
Philip Fisher
58No pass
Peter Lynch
75Pass
Joel Greenblatt
36No pass
Charlie Munger
42No pass
Terry Smith
43No pass
Questions about OptimizeRx
Is OptimizeRx a good stock to buy?
A business with weak numbers at a fair price. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the OptimizeRx AI analysis
What does OptimizeRx do?
OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. It is in Medical - Healthcare Information Services.
Does OptimizeRx pay a dividend?
No. OptimizeRx does not pay a dividend at the moment.
Is OptimizeRx stock halal?
Yes. OptimizeRx passes our halal screen: its business is permitted and its debt is 19% of its market value, under the 30% limit. How we check
How has OptimizeRx stock done over the past year?
Down 52.5% over the past twelve months, to $7.34. It traded between $4.54 and $15.46 and is 52.5% below its high.
Who are OptimizeRx's competitors?
The largest listed companies in the same industry are GE HealthCare Technologies, BrightSpring Health Services, Tempus AI and HealthEquity. The peers table on this page compares their profit, growth and price with OptimizeRx's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.